Premium
Response to treatment in pediatric ocular myasthenia gravis
Author(s) -
Xu Lori,
Castro Diana,
Reisch Joan S.,
Iannaccone Susan T.
Publication year - 2020
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.26745
Subject(s) - prednisone , myasthenia gravis , medicine , ocular myasthenia , pediatrics , retrospective cohort study , disease , juvenile , genetics , biology
Juvenile myasthenia gravis (JMG), a pediatric autoimmune neuromuscular junction disorder, includes generalized (GMG), and ocular (OMG) variants. We sought to determine whether differences existed between OMG and GMG children regarding demographics or treatment response. Methods We performed retrospective analysis of 60 children with JMG seen between 1990 and 2018. Osserman scores were used to define OMG and GMG. The myasthenia scale of Millichap and Dodge was used to assess treatment responses. Results There were no differences between GMG and OMG regarding time interval from disease onset to prednisone initiation ( P = .42), or treatment response according to Millichap and Dodge ( P = .12). Compared with GMG, OMG children showed younger age of disease onset and better outcomes after treatment. No OMG patients progressed to generalized disease during the follow‐up period. Discussion Compared with GMG, OMG patients had earlier disease onset and improved outcomes after treatment.